RXRX: Recursion Pharmaceuticals, Inc.
About
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Current Value
$7.521 Year Return
Current Value
$7.521 Year Return
Key Details
Market Cap
$2.90B
P/E Ratio
-4.88
1Y Stock Return
0.27%
1Y Revenue Growth
37.64%
Dividend Yield
0.00%
Price to Book
4.1
Strategies that include RXRX
Stock's related to RXRX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRSP | 61.39% | $4.16B | -16.24% | 0.00% |
| BEAM | 60.32% | $2.50B | +15.98% | 0.00% |
| NTLA | 54.72% | $1.50B | -47.71% | 0.00% |
| SW | 54.64% | $13.85B | +15.60% | 1.13% |
| NNOX | 53.07% | $450.45M | +23.79% | 0.00% |
| TWST | 52.40% | $3.06B | +82.51% | 0.00% |
| CNNE | 50.14% | $1.30B | +9.49% | 1.16% |
| MCFT | 49.40% | $351.70M | +1.45% | 0.00% |
| CLSK | 48.91% | $3.79B | +47.46% | 0.00% |
| FATE | 48.12% | $259.68M | -5.00% | 0.00% |
| W | 48.09% | $6.85B | +5.05% | 0.00% |
| RCKT | 47.99% | $1.23B | -46.83% | 0.00% |
| OPEN | 47.90% | $1.48B | -39.83% | 0.00% |
| KN | 47.88% | $1.72B | +19.49% | 0.00% |
| ABCL | 47.77% | $892.01M | -36.82% | 0.00% |
| FARO | 47.61% | $514.55M | +47.35% | 0.00% |
| DAN | 47.22% | $1.88B | -6.23% | 3.10% |
| VAC | 47.21% | $3.33B | +19.11% | 3.15% |
| SOFI | 47.04% | $16.59B | +92.33% | 0.00% |
| DDD | 46.72% | $447.55M | -43.20% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LPLA | 0.08% | $24.26B | +42.13% | 0.37% |
| T | -0.12% | $168.69B | +43.27% | 4.73% |
| GL | -0.14% | $8.70B | -16.80% | 0.91% |
| LNG | 0.19% | $47.75B | +24.59% | 0.84% |
| XBIO | -0.21% | $6.71M | +18.85% | 0.00% |
| CNA | 0.23% | $13.08B | +20.72% | 3.65% |
| HSY | -0.34% | $37.88B | +1.35% | 3.08% |
| MSDL | 0.38% | $1.87B | +3.06% | 7.06% |
| UNH | 0.43% | $520.14B | +3.57% | 1.47% |
| SUZ | -0.63% | $13.26B | +4.39% | 0.00% |
| MGPI | 0.68% | $1.01B | -49.94% | 1.03% |
| SO | 0.69% | $92.46B | +19.75% | 3.40% |
| CHE | 0.75% | $8.20B | -5.00% | 0.33% |
| THG | 0.82% | $5.59B | +20.97% | 2.19% |
| CAG | -0.96% | $13.29B | -5.98% | 5.01% |
| EQC | -1.03% | $164.22M | -92.06% | 0.00% |
| VHC | 1.05% | $17.15M | -39.63% | 0.00% |
| WTW | -1.06% | $30.99B | +24.81% | 1.13% |
| AGO | 1.12% | $4.50B | +21.96% | 1.40% |
| MANU | -1.15% | $2.92B | -11.01% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -21.90% | $74.13B | +26.36% | 0.46% |
| PGR | -19.43% | $144.85B | +49.74% | 0.46% |
| CBOE | -17.57% | $21.25B | +13.78% | 1.16% |
| CAH | -14.98% | $29.14B | +11.57% | 1.66% |
| COR | -14.95% | $45.81B | +16.21% | 0.89% |
| CHD | -13.49% | $26.23B | +13.34% | 1.05% |
| ACGL | -13.30% | $35.12B | +22.28% | 0.00% |
| AJG | -12.85% | $62.25B | +14.60% | 0.84% |
| CME | -11.58% | $86.19B | +14.50% | 1.94% |
| LMT | -10.95% | $121.58B | +13.58% | 2.48% |
| HUSA | -10.87% | $16.88M | -24.12% | 0.00% |
| NOC | -9.80% | $69.96B | +0.19% | 1.68% |
| RNR | -9.54% | $13.98B | +29.28% | 0.58% |
| PULM | -8.62% | $21.77M | +223.91% | 0.00% |
| CHKP | -8.46% | $20.55B | +25.46% | 0.00% |
| CYD | -8.41% | $370.18M | +10.76% | 4.19% |
| TCTM | -8.17% | $8.31M | -6.96% | 0.00% |
| WM | -7.75% | $86.73B | +22.36% | 1.39% |
| MMC | -7.54% | $105.88B | +7.18% | 1.41% |
| STG | -7.08% | $33.55M | -21.21% | 0.00% |
ETF's related to RXRX
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ARKG | 74.60% | $1.23B | 0.75% |
| ARKK | 64.57% | $6.85B | 0.75% |
| GNOM | 64.41% | $78.86M | 0.5% |
| KOMP | 63.12% | $2.23B | 0.2% |
| XBI | 60.93% | $6.82B | 0.35% |
| RSPA | 60.66% | $269.76M | 0% |
| IWO | 59.58% | $13.22B | 0.24% |
| IWC | 59.37% | $1.01B | 0.6% |
| VBK | 59.23% | $20.45B | 0.07% |
| QQA | 58.53% | $142.01M | 0% |
| ARTY | 58.37% | $694.02M | 0.47% |
| WTAI | 58.19% | $211.25M | 0.45% |
| XJH | 58.11% | $259.75M | 0.12% |
| EDOC | 57.96% | $41.74M | 0.68% |
| IBUY | 57.95% | $188.84M | 0.65% |
| ITEQ | 57.59% | $88.98M | 0.75% |
| IWM | 57.55% | $82.24B | 0.19% |
| BUZZ | 57.52% | $62.69M | 0.75% |
| XRT | 57.39% | $442.53M | 0.35% |
| VTWO | 57.37% | $12.95B | 0.1% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CCOR | 0.08% | $107.36M | 1.18% |
| BSCO | 0.44% | $2.14B | 0.1% |
| JUCY | -0.60% | $324.29M | 0.6% |
| CSHI | 0.66% | $481.10M | 0.38% |
| FLRN | 0.71% | $2.37B | 0.15% |
| DBA | 0.76% | $793.07M | 0.93% |
| JBBB | -0.80% | $1.36B | 0.49% |
| MINT | 0.91% | $11.84B | 0.35% |
| CLOI | -0.96% | $789.22M | 0.4% |
| CANE | -1.19% | $15.48M | 0.29% |
| XHLF | 1.26% | $903.51M | 0.03% |
| BIL | -1.69% | $34.60B | 0.1356% |
| TBIL | 1.77% | $4.51B | 0.15% |
| XBIL | -2.23% | $632.27M | 0.15% |
| DUSB | 2.53% | $855.44M | 0.15% |
| BILZ | -2.84% | $558.31M | 0.14% |
| CORN | -3.01% | $61.94M | 0.2% |
| SGOV | -3.18% | $28.86B | 0.09% |
| HDRO | 3.47% | $164.26M | 0.3% |
| FLTR | 3.79% | $1.86B | 0.14% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -30.63% | $195.31M | 0.85% |
| UUP | -27.63% | $386.70M | 0.77% |
| USDU | -27.11% | $211.42M | 0.5% |
| TAIL | -17.54% | $66.62M | 0.59% |
| WEAT | -8.97% | $123.72M | 0.28% |
| CTA | -8.83% | $392.57M | 0.76% |
| KMLM | -7.91% | $333.70M | 0.9% |
| AGZD | -7.04% | $132.89M | 0.23% |
| EQLS | -6.84% | $8.94M | 1% |
| KCCA | -6.82% | $124.61M | 0.87% |
| IBHD | -6.54% | $312.37M | 0.35% |
| SGOV | -3.18% | $28.86B | 0.09% |
| CORN | -3.01% | $61.94M | 0.2% |
| BILZ | -2.84% | $558.31M | 0.14% |
| XBIL | -2.23% | $632.27M | 0.15% |
| BIL | -1.69% | $34.60B | 0.1356% |
| CANE | -1.19% | $15.48M | 0.29% |
| CLOI | -0.96% | $789.22M | 0.4% |
| JBBB | -0.80% | $1.36B | 0.49% |
| JUCY | -0.60% | $324.29M | 0.6% |
News
SeekingAlpha
Recursion Pharmaceuticals is reshaping drug discovery with AI, strategic partnerships, and financial discipline for long-term investors. Explore more details here.
Yahoo
We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other worst ARK stocks to buy according to short sellers. Cathie Wood of ARK Investment is one of Wall Street’s most well-known hedge […]
Yahoo
REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatmentAdditional 4 patients demonstrated a best respo
SeekingAlpha
Exciting updates on potential Recursion Pharmaceuticals, Inc. treatments for cerebral cavernous malformation and solid tumors. Click for my RXRX update.
Yahoo
We recently compiled a list of the Jim Cramer’s Lightning Round: 7 Stocks to Watch. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other stocks featured in Jim Cramer’s Lightning Round. Jim Cramer, the host of Mad Money, recently offered his views on several key […]
Yahoo
First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile in Solid tumors and Lymphoma>100,000 patients in the US and EU5 initially addressable SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company deco
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.